NCT02082210 2020-12-19A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced CancerEli Lilly and CompanyPhase 1/2 Completed97 enrolled 20 charts
NCT01602289 2015-06-08A Study of LY2875358 in Japanese Participants With Advanced CancerEli Lilly and CompanyPhase 1 Completed17 enrolled